{"sent_idx": "32", "frame_idx": "4", "ev": "Addition of bevacizumab significantly prolonged progression-free survival (PFS) compared with placebo (median, 6.7 vs 5.3 months; hazard ratio (HR), 0.80; P=0.0037) and increased overall response rate (46.0% vs 37.4% P=0.0315).", "icos": [["1", "placebo", "bevacizumab", "progression - free survival ( PFS )"]], "sample": "x"}
{"sent_idx": "32", "frame_idx": "5", "ev": "Addition of bevacizumab significantly prolonged progression-free survival (PFS) compared with placebo (median, 6.7 vs 5.3 months; hazard ratio (HR), 0.80; P=0.0037) and increased overall response rate (46.0% vs 37.4% P=0.0315).", "icos": [["1", "placebo", "bevacizumab", "overall response rate"]], "sample": "x"}
{"sent_idx": "41", "frame_idx": "8", "ev": "Median OS was increased from 3.8 to 5.2 months in the ramucirumab arm compared with the placebo group; HR 0.776; 95% CI 0.603\u20130.998; P=0.047.", "icos": [["1", "ramucirumab", "placebo", "Median OS"]], "sample": "x"}
{"sent_idx": "112", "frame_idx": "21", "ev": "In the presence of liver metastasis, bevacizumab treatment was associated with a marked decrease in plasma Ang-2 levels at progression while in the chemotherapy-treated group there was a trend towards increased plasma Ang-2 levels at progression (Supplementary Table S2).", "icos": [["1", "chemotherapy", "bevacizumab", "plasma Ang - 2 levels"]], "sample": "x"}
{"sent_idx": "145", "frame_idx": "22", "ev": "In the bevacizumab-treated group, however, Ang-2 levels were decreased at progression, compared with the chemotherapy only group (2217.0 vs 2891.0 pg ml\u22121).", "icos": [["1", "chemotherapy", "bevacizumab -", "Ang - 2 levels"]], "sample": "x"}
{"sent_idx": "35", "frame_idx": "7", "ev": "Yet, in subgroup analyses, a survival benefit from bevacizumab was observed in patients enrolled in North and Latin America (HR 0.63; 95% CI 0.43\u20130.94), whereas patients enrolled in Asia had no benefit (90% from Japan and Korea; HR 0.97; 95% CI 0.75\u20131.25) and European patients showed intermediate-risk reduction (HR 0.85; 95% CI 0.63\u20131.14).", "icos": [["0.9862839", "bevacizumab", "bevacizumab", "survival benefit"], ["0.9698732", "bevacizumab", "bevacizumab .", "survival benefit"], ["0.75035334", "bevacizumab", "becacizumab", "survival benefit"], ["0.32775018", "bevacizumab", "bevacizumab -", "survival benefit"], ["0.19332772", "bevacizumab", "ramucirumab", "survival benefit"]], "sample": "c"}
{"sent_idx": "97", "frame_idx": "14", "ev": "In multiple Cox regression models, Ang-2 levels were not predictive of benefit from bevacizumab with respect to PFS or OS.", "icos": [["0.65245605", "bevacizumab", "chemotherapy", "PFS or OS ."], ["0.2837041", "bevacizumab", "placebo", "PFS or OS ."], ["0.06976419", "bevacizumab", "bevacizumab", "PFS or OS ."], ["0.01594579", "bevacizumab", "becacizumab", "PFS or OS ."], ["0.013164798", "bevacizumab", "bevacizumab -", "PFS or OS ."]], "sample": "c"}
{"sent_idx": "97", "frame_idx": "15", "ev": "In multiple Cox regression models, Ang-2 levels were not predictive of benefit from bevacizumab with respect to PFS or OS.", "icos": [["0.97267693", "bevacizumab", "bevacizumab", "Ang - 2 levels"], ["0.928129", "bevacizumab", "chemotherapy", "Ang - 2 levels"], ["0.87694436", "bevacizumab", "placebo", "Ang - 2 levels"], ["0.7018993", "bevacizumab", "bevacizumab -", "Ang - 2 levels"], ["0.64007324", "bevacizumab", "bevacizumab .", "Ang - 2 levels"]], "sample": "c"}
